^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

AMD1 inhibitor

Related drugs:
1d
Cysteine Restriction Induces Ferroptosis Depending on the S-adenosylmethionine and Polyamine Biosynthetic Pathways in Hepatic Cancer Cells. (PubMed, Gastro Hep Adv)
Inhibitors of ferroptosis (Fer-1), necroptosis (GSK872), SAM synthesis (cycloleucine), or polyamine synthesis (sardomozide and difluoromethylornithine) were used...These results suggest that cysteine-glutathione and SAM-polyamine metabolic pathways are critical modulators of ferroptosis of hepatic cancer cells. Since normal liver cells were more resistant to ferroptosis than cancer cells, cysteine restriction may be exploited in treating hepatic cancer by inducing ferroptosis specifically in cancer cells without affecting normal cells in the liver.
Journal
|
ANXA5 (Annexin A5) • MAT2A (Methionine Adenosyltransferase 2A)
over1year
ASPIRE: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (clinicaltrials.gov)
P2/3, N=600, Recruiting, Panbela Therapeutics, Inc. | N=150 --> 600 | Trial completion date: May 2024 --> Jan 2027 | Trial primary completion date: May 2024 --> Aug 2026
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
gemcitabine • albumin-bound paclitaxel • ivospemin (SBP-101)
2years
Effect of Ivospemin and Difluoromethylornithine Polyamine Inhibitors on Viability of Myeloma Cell Lines (ASH 2023)
The polyamine inhibitors,Ivospemin and DFMO, exhibited a marked anti-proliferative effect in the four human MM cell lines studied when used alone or in combination. These results confirm the anti-neoplastic potential of SBP-101 and DFMO and offer a compelling rationale for its clinical development as a potentially promising treatment option for multiple myeloma. Fig.
Preclinical
|
ANXA5 (Annexin A5)
|
ivospemin (SBP-101)